FibroGen To Present Data From Dose Escalation Phase 1b Study of FG-3246 Plus Enzalutamide At 2024 American Society of Clinical Oncology Annual Meeting May 31-Jun. 4
FibroGen To Present Data From Dose Escalation Phase 1b Study of FG-3246 Plus Enzalutamide At 2024 American Society of Clinical Oncology Annual Meeting May 31-Jun. 4
FibroGen Announces Clinical Data From Dose Escalation Phase 1b Study of FG-3246 (FOR46) In...
Kind Pharmaceuticals Announces Settlement
HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr. Dong Liu
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet
The FibroGen, Inc. (NASDAQ:FGEN) share price has softened a substantial 28% over the previous 30 days, handing back much of the gains the stock has made lately. For any long-term shareholders, the
FibroGen, Inc.'s (NASDAQ:FGEN) Latest 43% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Key Insights Institutions' substantial holdings in FibroGen implies that they have significant influence over the company's share price A total of 8 investors have a majority stake in the company wi
FibroGen Falls After Early-stage Data for Prostate Cancer Drug
Top Midday Decliners
View (VIEW) said late Tuesday that it received approval from key shareholders for a balance sheet restructuring plan. Shares slumped about 60%, with intraday trading volume at over 1.1 million versus
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (A
FibroGen, Acorda Therapeutics, Enveric Biosciences Among Healthcare Movers
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise
FibroGen (FGEN) said late Tuesday it saw "encouraging" data from a Fortis Therapeutics-sponsored phase 1 study of FG-3246 for patients with metastatic castration-resistant prostate cancer whose tumors
FibroGen (FGEN) Gets a Sell From Goldman Sachs
FibroGen Reports Data From Fortis Therapeutics-Sponsored Phase 1 Study Of FG-3246
In the efficacy analysis, PSA reductions of ≥ 50% were observed in 36% of PSA evaluable patients. For RECIST evaluable patients, 20% met the criteria of a partial response, or tumor reduction in size
FibroGen Announces Topline Results From Phase 1 Monotherapy Study of FG-3246 in Patients With Metastatic Castration-Resistant Prostate Cancer
FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors have progressed on at least one androgen receptor-signaling inhibitor (ARSI).
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Sector Update: Health Care Stocks Higher in Afternoon Trading
Health care stocks rose Tuesday afternoon with the NYSE Health Care Index increasing 0.6% and the Health Care Select Sector SPDR Fund (XLV) gaining 0.5%.
FibroGen Shares Jump After CEO Stock Purchase
FibroGen (FGEN) shares climbed 13% in recent Tuesday trading after Chief Executive Officer Thane Wettig recently bought 50,000 of the company's common shares at $1.9094 each. Wettig has control over 4
No Data